| Ytd | -1.77% | |
| 1y | -30.77% |
| Open | 0.83 | Prev Close | 0.85 | Low | 0.82 | High | 0.86 | Mkt Cap | 86.16M |
| Vol | 1.04M | Avg Vol | 1.49M | EPS | -0.31 | P/E | -2.77 | Forward P/E | -3.02 |
| Beta | 1.09 | Short Ratio | 3.51 | Inst. Own | 1.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.88 | 200-d Avg | 0.99 | 1yr Est | 4.85 |
ONCY News
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-
Designation supports development in an estimated $1 billion market where there are no FDA-approved t
REO 033 builds upon the previously reported REO 022 study, which more than doubled historical standa
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) w
Oncolytics shares rise as pelareorep shows 19.5-month response durability and higher response rates
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s
Company to leverage strong durability and survival data in second-line and later metastatic squamous
On April 6, 2026, Oncolytics Biotech Inc. (the "Company") entered into an Open Market Sale A
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by
During Monday's trading, 1214 companies set new 52-week lows.
Stocks Which Set New 52-Week Low Yesterday, October 9th